A Pilot Study of Circulating Endothelial and Hematopoietic Progenitor Cells in Children with Sarcomas

Kamnesh Pradhan, Julie A. Mund, Heather L. Claussen, Yasmin C. Gosiengfiao, Vlad C. Radulescu, Jennifer J. Ballard, Ziyue Liu, Terry Vik, Jamie Case

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Utilizing a multiparametric flow cytometry protocol, we assessed various cell types implicated in tumor angiogenesis that were found circulating in the peripheral blood of children with sarcomas (cases) based on their cell surface antigen expression. Circulating endothelial cells (CECs), endothelial colony-forming cells (ECFCs), and the ratio of 2 distinct populations of circulating hematopoietic stem and progenitor cells (CHSPCs), the proangiogenic CHSPCs (pCHSPCs) and nonangiogenic CHSPCs (nCHSPCs) were enumerated. Multiparametric flow cytometry was analyzed in cases at baseline and at 4 additional timepoints until the end of treatment and levels compared with each other and with healthy controls. At all timepoints, cases had significantly lower levels of CECs, but elevated ECFCs and a pCHSPC:nCHSPC ratio compared with controls (all P-values <0.05). There was no significant difference in any of the cell types analyzed based on tumor histology, stage (localized vs. metastatic), or tumor size. After treatment, only the CECs among the complete responders were significantly lower at end of therapy (P<0.01) compared with nonresponders, whereas the ECFCs among all cases significantly increased (P<0.05) compared with baseline. No decline in the pCHSPC:nCHSPC ratio was observed despite tumor response. On the basis of these results, a validation of CECs as prognostic biomarker is now warranted.

Original languageEnglish
Pages (from-to)443-448
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume37
Issue number6
DOIs
StatePublished - Aug 6 2015

Fingerprint

Hematopoietic Stem Cells
Sarcoma
Endothelial Cells
Neoplasms
Flow Cytometry
Surface Antigens
Endothelial Progenitor Cells
Histology
Therapeutics
Biomarkers
Population

Keywords

  • chemotherapy
  • endothelial cells
  • progenitor cells
  • sarcomas

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

A Pilot Study of Circulating Endothelial and Hematopoietic Progenitor Cells in Children with Sarcomas. / Pradhan, Kamnesh; Mund, Julie A.; Claussen, Heather L.; Gosiengfiao, Yasmin C.; Radulescu, Vlad C.; Ballard, Jennifer J.; Liu, Ziyue; Vik, Terry; Case, Jamie.

In: Journal of Pediatric Hematology/Oncology, Vol. 37, No. 6, 06.08.2015, p. 443-448.

Research output: Contribution to journalArticle

Pradhan, Kamnesh ; Mund, Julie A. ; Claussen, Heather L. ; Gosiengfiao, Yasmin C. ; Radulescu, Vlad C. ; Ballard, Jennifer J. ; Liu, Ziyue ; Vik, Terry ; Case, Jamie. / A Pilot Study of Circulating Endothelial and Hematopoietic Progenitor Cells in Children with Sarcomas. In: Journal of Pediatric Hematology/Oncology. 2015 ; Vol. 37, No. 6. pp. 443-448.
@article{ec0f14279f3a4e019272c410dec1c19f,
title = "A Pilot Study of Circulating Endothelial and Hematopoietic Progenitor Cells in Children with Sarcomas",
abstract = "Utilizing a multiparametric flow cytometry protocol, we assessed various cell types implicated in tumor angiogenesis that were found circulating in the peripheral blood of children with sarcomas (cases) based on their cell surface antigen expression. Circulating endothelial cells (CECs), endothelial colony-forming cells (ECFCs), and the ratio of 2 distinct populations of circulating hematopoietic stem and progenitor cells (CHSPCs), the proangiogenic CHSPCs (pCHSPCs) and nonangiogenic CHSPCs (nCHSPCs) were enumerated. Multiparametric flow cytometry was analyzed in cases at baseline and at 4 additional timepoints until the end of treatment and levels compared with each other and with healthy controls. At all timepoints, cases had significantly lower levels of CECs, but elevated ECFCs and a pCHSPC:nCHSPC ratio compared with controls (all P-values <0.05). There was no significant difference in any of the cell types analyzed based on tumor histology, stage (localized vs. metastatic), or tumor size. After treatment, only the CECs among the complete responders were significantly lower at end of therapy (P<0.01) compared with nonresponders, whereas the ECFCs among all cases significantly increased (P<0.05) compared with baseline. No decline in the pCHSPC:nCHSPC ratio was observed despite tumor response. On the basis of these results, a validation of CECs as prognostic biomarker is now warranted.",
keywords = "chemotherapy, endothelial cells, progenitor cells, sarcomas",
author = "Kamnesh Pradhan and Mund, {Julie A.} and Claussen, {Heather L.} and Gosiengfiao, {Yasmin C.} and Radulescu, {Vlad C.} and Ballard, {Jennifer J.} and Ziyue Liu and Terry Vik and Jamie Case",
year = "2015",
month = "8",
day = "6",
doi = "10.1097/MPH.0000000000000386",
language = "English",
volume = "37",
pages = "443--448",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - A Pilot Study of Circulating Endothelial and Hematopoietic Progenitor Cells in Children with Sarcomas

AU - Pradhan, Kamnesh

AU - Mund, Julie A.

AU - Claussen, Heather L.

AU - Gosiengfiao, Yasmin C.

AU - Radulescu, Vlad C.

AU - Ballard, Jennifer J.

AU - Liu, Ziyue

AU - Vik, Terry

AU - Case, Jamie

PY - 2015/8/6

Y1 - 2015/8/6

N2 - Utilizing a multiparametric flow cytometry protocol, we assessed various cell types implicated in tumor angiogenesis that were found circulating in the peripheral blood of children with sarcomas (cases) based on their cell surface antigen expression. Circulating endothelial cells (CECs), endothelial colony-forming cells (ECFCs), and the ratio of 2 distinct populations of circulating hematopoietic stem and progenitor cells (CHSPCs), the proangiogenic CHSPCs (pCHSPCs) and nonangiogenic CHSPCs (nCHSPCs) were enumerated. Multiparametric flow cytometry was analyzed in cases at baseline and at 4 additional timepoints until the end of treatment and levels compared with each other and with healthy controls. At all timepoints, cases had significantly lower levels of CECs, but elevated ECFCs and a pCHSPC:nCHSPC ratio compared with controls (all P-values <0.05). There was no significant difference in any of the cell types analyzed based on tumor histology, stage (localized vs. metastatic), or tumor size. After treatment, only the CECs among the complete responders were significantly lower at end of therapy (P<0.01) compared with nonresponders, whereas the ECFCs among all cases significantly increased (P<0.05) compared with baseline. No decline in the pCHSPC:nCHSPC ratio was observed despite tumor response. On the basis of these results, a validation of CECs as prognostic biomarker is now warranted.

AB - Utilizing a multiparametric flow cytometry protocol, we assessed various cell types implicated in tumor angiogenesis that were found circulating in the peripheral blood of children with sarcomas (cases) based on their cell surface antigen expression. Circulating endothelial cells (CECs), endothelial colony-forming cells (ECFCs), and the ratio of 2 distinct populations of circulating hematopoietic stem and progenitor cells (CHSPCs), the proangiogenic CHSPCs (pCHSPCs) and nonangiogenic CHSPCs (nCHSPCs) were enumerated. Multiparametric flow cytometry was analyzed in cases at baseline and at 4 additional timepoints until the end of treatment and levels compared with each other and with healthy controls. At all timepoints, cases had significantly lower levels of CECs, but elevated ECFCs and a pCHSPC:nCHSPC ratio compared with controls (all P-values <0.05). There was no significant difference in any of the cell types analyzed based on tumor histology, stage (localized vs. metastatic), or tumor size. After treatment, only the CECs among the complete responders were significantly lower at end of therapy (P<0.01) compared with nonresponders, whereas the ECFCs among all cases significantly increased (P<0.05) compared with baseline. No decline in the pCHSPC:nCHSPC ratio was observed despite tumor response. On the basis of these results, a validation of CECs as prognostic biomarker is now warranted.

KW - chemotherapy

KW - endothelial cells

KW - progenitor cells

KW - sarcomas

UR - http://www.scopus.com/inward/record.url?scp=84938593887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938593887&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000000386

DO - 10.1097/MPH.0000000000000386

M3 - Article

C2 - 26115508

AN - SCOPUS:84938593887

VL - 37

SP - 443

EP - 448

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 6

ER -